Cargando…

ATRT-09. IDENTIFICATION OF POTENTIAL GENETIC DRIVERS OF METHOTREXATE (MTX) RESISTANCE IN ATYPICAL TERATOID RHABDOID TUMOURS (ATRT) THROUGH A GENOME-WIDE RNAI SCREEN

ATRT of the CNS constitute a group of rare and aggressive early childhood tumors with poor prognosis. While there are differing chemotherapeutic regimens for ATRT, high-dose MTX is a crucial component of many therapeutic protocols. Currently, the biological mechanisms contributing to the generation...

Descripción completa

Detalles Bibliográficos
Autores principales: Kannappan, Sunand, Gupa, Mehul, Kang, SungMyung, Tran, Andy Son, Thakur, Satbir Singh, Jain, Mohit, Narendran, Aru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168191/
http://dx.doi.org/10.1093/neuonc/noab090.008
_version_ 1783701839638691840
author Kannappan, Sunand
Gupa, Mehul
Kang, SungMyung
Tran, Andy Son
Thakur, Satbir Singh
Jain, Mohit
Narendran, Aru
author_facet Kannappan, Sunand
Gupa, Mehul
Kang, SungMyung
Tran, Andy Son
Thakur, Satbir Singh
Jain, Mohit
Narendran, Aru
author_sort Kannappan, Sunand
collection PubMed
description ATRT of the CNS constitute a group of rare and aggressive early childhood tumors with poor prognosis. While there are differing chemotherapeutic regimens for ATRT, high-dose MTX is a crucial component of many therapeutic protocols. Currently, the biological mechanisms contributing to the generation of MTX resistance in ATRT are unknown. To identify genes involved in MTX resistance in ATRT, an unbiased genome-wide RNAi screen on ATRT cell lines was conducted using 24,000 distinct shRNAs covering 8,000 genes. ATRT cells were transfected with a retrovirus containing pRS-shRNA vectors and treated with puromycin for selection. The resulting cells were treated with MTX to identify resistant clones and resistant colonies were then isolated and amplified individually. Presence of shRNA inserts in each colony was determined by PCR using pRS forward and reverse primers. PCR products within each of the three resistant colonies were sequenced, leading to the identification of three distinct genes, TGIF1, HIF3A and PGAM2, as potential indicators of resistance. Western blotting verified depletion of these proteins in their respective colonies. Proliferation assays were then conducted on cells from each resistant colony alongside control cells to confirm that the identified drivers conferred resistance. Sensitivity to MTX was significantly lower in TGIF1-depleted (IC50=212±8.48nM, n=3), HIF3A-depleted (IC50=52±4.68nM, n=3) and PGAM2-depleted (IC50=41±4.13nM, n=3) cells compared to control cells (IC50=19±2.87nM, n=3), (p<0.001). In addition, more than 60% of TGIF1, HIF3A, and PGAM2-depleted cells survived the maximum MTX treatment (100nM), while less than 20% of control cells survived this treatment. Our study using an unbiased genome-wide RNAi screen approach has shown that depletion of TGIF1, HIF3A and PGAM2 are potential molecular markers of MTX resistance in ATRT. Screening for their occurrence may help to identify patients at high risk of MTX resistance and may also serve as targets for future novel therapeutics development.
format Online
Article
Text
id pubmed-8168191
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-81681912021-06-02 ATRT-09. IDENTIFICATION OF POTENTIAL GENETIC DRIVERS OF METHOTREXATE (MTX) RESISTANCE IN ATYPICAL TERATOID RHABDOID TUMOURS (ATRT) THROUGH A GENOME-WIDE RNAI SCREEN Kannappan, Sunand Gupa, Mehul Kang, SungMyung Tran, Andy Son Thakur, Satbir Singh Jain, Mohit Narendran, Aru Neuro Oncol Atypical Teratoid Rhabdoid Tumors ATRT of the CNS constitute a group of rare and aggressive early childhood tumors with poor prognosis. While there are differing chemotherapeutic regimens for ATRT, high-dose MTX is a crucial component of many therapeutic protocols. Currently, the biological mechanisms contributing to the generation of MTX resistance in ATRT are unknown. To identify genes involved in MTX resistance in ATRT, an unbiased genome-wide RNAi screen on ATRT cell lines was conducted using 24,000 distinct shRNAs covering 8,000 genes. ATRT cells were transfected with a retrovirus containing pRS-shRNA vectors and treated with puromycin for selection. The resulting cells were treated with MTX to identify resistant clones and resistant colonies were then isolated and amplified individually. Presence of shRNA inserts in each colony was determined by PCR using pRS forward and reverse primers. PCR products within each of the three resistant colonies were sequenced, leading to the identification of three distinct genes, TGIF1, HIF3A and PGAM2, as potential indicators of resistance. Western blotting verified depletion of these proteins in their respective colonies. Proliferation assays were then conducted on cells from each resistant colony alongside control cells to confirm that the identified drivers conferred resistance. Sensitivity to MTX was significantly lower in TGIF1-depleted (IC50=212±8.48nM, n=3), HIF3A-depleted (IC50=52±4.68nM, n=3) and PGAM2-depleted (IC50=41±4.13nM, n=3) cells compared to control cells (IC50=19±2.87nM, n=3), (p<0.001). In addition, more than 60% of TGIF1, HIF3A, and PGAM2-depleted cells survived the maximum MTX treatment (100nM), while less than 20% of control cells survived this treatment. Our study using an unbiased genome-wide RNAi screen approach has shown that depletion of TGIF1, HIF3A and PGAM2 are potential molecular markers of MTX resistance in ATRT. Screening for their occurrence may help to identify patients at high risk of MTX resistance and may also serve as targets for future novel therapeutics development. Oxford University Press 2021-06-01 /pmc/articles/PMC8168191/ http://dx.doi.org/10.1093/neuonc/noab090.008 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Atypical Teratoid Rhabdoid Tumors
Kannappan, Sunand
Gupa, Mehul
Kang, SungMyung
Tran, Andy Son
Thakur, Satbir Singh
Jain, Mohit
Narendran, Aru
ATRT-09. IDENTIFICATION OF POTENTIAL GENETIC DRIVERS OF METHOTREXATE (MTX) RESISTANCE IN ATYPICAL TERATOID RHABDOID TUMOURS (ATRT) THROUGH A GENOME-WIDE RNAI SCREEN
title ATRT-09. IDENTIFICATION OF POTENTIAL GENETIC DRIVERS OF METHOTREXATE (MTX) RESISTANCE IN ATYPICAL TERATOID RHABDOID TUMOURS (ATRT) THROUGH A GENOME-WIDE RNAI SCREEN
title_full ATRT-09. IDENTIFICATION OF POTENTIAL GENETIC DRIVERS OF METHOTREXATE (MTX) RESISTANCE IN ATYPICAL TERATOID RHABDOID TUMOURS (ATRT) THROUGH A GENOME-WIDE RNAI SCREEN
title_fullStr ATRT-09. IDENTIFICATION OF POTENTIAL GENETIC DRIVERS OF METHOTREXATE (MTX) RESISTANCE IN ATYPICAL TERATOID RHABDOID TUMOURS (ATRT) THROUGH A GENOME-WIDE RNAI SCREEN
title_full_unstemmed ATRT-09. IDENTIFICATION OF POTENTIAL GENETIC DRIVERS OF METHOTREXATE (MTX) RESISTANCE IN ATYPICAL TERATOID RHABDOID TUMOURS (ATRT) THROUGH A GENOME-WIDE RNAI SCREEN
title_short ATRT-09. IDENTIFICATION OF POTENTIAL GENETIC DRIVERS OF METHOTREXATE (MTX) RESISTANCE IN ATYPICAL TERATOID RHABDOID TUMOURS (ATRT) THROUGH A GENOME-WIDE RNAI SCREEN
title_sort atrt-09. identification of potential genetic drivers of methotrexate (mtx) resistance in atypical teratoid rhabdoid tumours (atrt) through a genome-wide rnai screen
topic Atypical Teratoid Rhabdoid Tumors
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168191/
http://dx.doi.org/10.1093/neuonc/noab090.008
work_keys_str_mv AT kannappansunand atrt09identificationofpotentialgeneticdriversofmethotrexatemtxresistanceinatypicalteratoidrhabdoidtumoursatrtthroughagenomewidernaiscreen
AT gupamehul atrt09identificationofpotentialgeneticdriversofmethotrexatemtxresistanceinatypicalteratoidrhabdoidtumoursatrtthroughagenomewidernaiscreen
AT kangsungmyung atrt09identificationofpotentialgeneticdriversofmethotrexatemtxresistanceinatypicalteratoidrhabdoidtumoursatrtthroughagenomewidernaiscreen
AT tranandyson atrt09identificationofpotentialgeneticdriversofmethotrexatemtxresistanceinatypicalteratoidrhabdoidtumoursatrtthroughagenomewidernaiscreen
AT thakursatbirsingh atrt09identificationofpotentialgeneticdriversofmethotrexatemtxresistanceinatypicalteratoidrhabdoidtumoursatrtthroughagenomewidernaiscreen
AT jainmohit atrt09identificationofpotentialgeneticdriversofmethotrexatemtxresistanceinatypicalteratoidrhabdoidtumoursatrtthroughagenomewidernaiscreen
AT narendranaru atrt09identificationofpotentialgeneticdriversofmethotrexatemtxresistanceinatypicalteratoidrhabdoidtumoursatrtthroughagenomewidernaiscreen